Partner Don Schroeder was quoted in a Society for Human Resource Management (SHRM) article, “New NLRB Acting Chairman May Tilt Board Pro-Business,” covering President Donald Trump’s naming of Philip Miscimarra as acting chairman of the National Labor Relations Board (NLRB) and the agency’s shift toward business interests.
While the Trump administration’s decision to place Miscimarra at the helm of the NLRB marks a change in the agency’s direction, Schroeder notes that dramatic changes will not be seen until the two vacancies left on the board have been filled. Miscimarra will have a say on current cases on the NLRB’s agenda as acting chair, however, Schroeder predicts that the Trump administration will name its nominees within 60 days.
While the Trump administration’s decision to place Miscimarra at the helm of the NLRB marks a change in the agency’s direction, Schroeder notes that dramatic changes will not be seen until the two vacancies left on the board have been filled. Miscimarra will have a say on current cases on the NLRB’s agenda as acting chair, however, Schroeder predicts that the Trump administration will name its nominees within 60 days.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”